LLL12

目录号: HY-19536 纯度: 99.45%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

LLL12 是一种 STAT3 小分子抑制剂，抑制 STAT3 磷酸化。LLL12 增强顺铂 (HY-17394) 和紫杉醇 (HY-B0015) 对卵巢癌症细胞生成、迁徙、和生长的抑制作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

LLL12 Chemical Structure

CAS No. : 1260247-42-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥1200	In-stock
5 mg	￥3500	In-stock
10 mg	￥5800	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

LLL12 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

查看所有亚型

STAT3 STAT5 STAT6 STAT1

生物活性
纯度 & 产品资料
参考文献

生物活性

LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth^[1].

IC₅₀ & Target^[1]

p-STAT3

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	0.19 μM Compound: LLL12	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24176397]
HEL	IC₅₀	1.46 μM Compound: LLL12	Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
HPAC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
HT-29	IC₅₀	0.11 μM Compound: LLL12	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24176397]
MDA-MB-231	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
MDA-MB-468	IC₅₀	0.73 μM Compound: LLL12	Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
PANC-1	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
SJRH30	IC₅₀	0.47 μM Compound: 13, LLL12	Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay	[PMID: 23651330]
SK-BR-3	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
U2OS	IC₅₀	1 μM Compound: 13, LLL12	Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay	[PMID: 23651330]
U-373MG ATCC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]
U-87MG ATCC	IC₅₀	0.16 μM Compound: 13, LLL12	Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23651330]

体外研究
(In Vitro)

LLL12 (0.01-1 μM; 72 h) 在顺铂 (0.5 μM, 2.5 μM) 和紫杉醇 (0.25 μM, 0.5 μM) 作用下均能抑制卵巢癌细胞系的细胞活力^[1]。
LLL12 (0.25-1.0μM) 抑制卵巢癌细胞系中 STAT3 磷酸化 (Tyr705)^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines
Concentration:	0.25, 0.5, and 1 μM for A2780 and OVCAR5; 1, 2.5, and 5 μM for SKOV3 and CAOV-3
Incubation Time:	72 hours
Result:	Inhibited STAT3 phosphorylation at Tyr705.

体内研究
(In Vivo)

LLL12 (5 mg/kg; 腹腔注射; 每天 1 次, 共 13 天) 在小鼠骨肉瘤细胞和肿瘤生长中表现出强大的生长抑制活性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse xenografts with SJSA or OS-33 osteosarcoma cells^[2]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; once daily for 13 days
Result:	Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice.

分子量

303.29

Formula

C₁₄H₉NO₅S

CAS 号

1260247-42-4

性状

固体

颜色

Light yellow to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (329.72 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2972 mL	16.4859 mL	32.9717 mL
5 mM	0.6594 mL	3.2972 mL	6.5943 mL
10 mM	0.3297 mL	1.6486 mL	3.2972 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 2% DMSO 40% PEG300 5% Tween-80 53% Saline
Solubility: 0.5 mg/mL (1.65 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.45%

选择批次：

Data Sheet (630 KB) SDS (251 KB)

COA (203 KB) HNMR (144 KB) RP-HPLC (161 KB) LCMS (383 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. [Content Brief]

[2]. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. [Content Brief]

LLL12 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2972 mL	16.4859 mL	32.9717 mL	82.4294 mL
	5 mM	0.6594 mL	3.2972 mL	6.5943 mL	16.4859 mL
	10 mM	0.3297 mL	1.6486 mL	3.2972 mL	8.2429 mL
	15 mM	0.2198 mL	1.0991 mL	2.1981 mL	5.4953 mL
	20 mM	0.1649 mL	0.8243 mL	1.6486 mL	4.1215 mL
	25 mM	0.1319 mL	0.6594 mL	1.3189 mL	3.2972 mL
	30 mM	0.1099 mL	0.5495 mL	1.0991 mL	2.7476 mL
	40 mM	0.0824 mL	0.4121 mL	0.8243 mL	2.0607 mL
	50 mM	0.0659 mL	0.3297 mL	0.6594 mL	1.6486 mL
	60 mM	0.0550 mL	0.2748 mL	0.5495 mL	1.3738 mL
	80 mM	0.0412 mL	0.2061 mL	0.4121 mL	1.0304 mL
	100 mM	0.0330 mL	0.1649 mL	0.3297 mL	0.8243 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LLL121260247-42-4LLL 12LLL-12STATInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

LLL12

Customer Review